Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opemalirsen (AZD2373) in Renal Impairment
NCT07154901Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Primary completion
- Jun 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of opemalirsen in renal impairment (RI) (4 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Zero to Infinity, Area Under the Plasma Concentration-Time Curve from Zero to the Last Quantifiable Concentration and 1 more. Started Aug 2025; status: completed.
02
Drugs
opemalirsen
03
Conditions
renal impairment (RI)
Beyond the preview
Go deeper on NCT07154901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154901.